GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial
of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction
syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Phase:
Phase 3
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)